Efficacy and safety of SABR/partial-SABR combined with axitinib and toripalimab in recurrent or metastatic renal cell carcinoma: Preliminary results from a prospective phase 2 trial.

ABSTRACT: The present study aimed to investigate the safety and efficacy of the combination of axitinib, toripalimab and stereotactic ablative body radiotherapy (SABR) in the treatment of recurrent or metastatic renal cell carcinoma (RCC). The present study was a single-center, prospective study in which all patients received a treatment regimen consisting of axitinib combined with toripalimab and comprehensive multi-lesion SABR. The primary endpoint was progression-free survival (PFS)1 (start of radiotherapy to first disease progression), while secondary endpoints included PFS2 (start of radiotherapy to second-line systemic treatment due to disease progression), overall survival (OS), local control, objective response rate (ORR) and disease control rate (DCR). Adverse events were assessed according

SUBMITTER: Hu K 

PROVIDER: S-EPMC12150836 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature